Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation

Sophie Deckx, Ward Heggermont, Paolo Carai, Marieke Rienks, Tom Dresselaers, Uwe Himmelreich, Rick van Leeuwen, Wies Lommen, Jolanda van der Velden, Arantxa Gonzalez, Javier Diez, Anna-Pia Papageorgiou, Stephane Heymans

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)110-124
Number of pages15
JournalMatrix Biology
Volume66
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Hypertension
  • Aging
  • Diastolic dysfunction
  • Matrix
  • Fibrosis
  • Osteoglycin
  • PRESERVED EJECTION FRACTION
  • LEUCINE-RICH PROTEOGLYCANS
  • HEART-FAILURE
  • MYOCARDIAL-INFARCTION
  • DISEASE
  • COLLAGEN
  • STIFFNESS
  • ABNORMALITIES
  • FIBROBLASTS
  • PREVALENCE

Cite this

Deckx, S., Heggermont, W., Carai, P., Rienks, M., Dresselaers, T., Himmelreich, U., van Leeuwen, R., Lommen, W., van der Velden, J., Gonzalez, A., Diez, J., Papageorgiou, A-P., & Heymans, S. (2018). Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biology, 66, 110-124. https://doi.org/10.1016/j.matbio.2017.09.002